Probability of survival

A lower bound on the overall effect of crossover, which can both create and destroy instances of a given schema, can be estimated by calculating the probability, Pc S), that crossover leaves a schema S unaltered. Let be the probability that the crossover operation will be applied to a string. Since a schema S will be destroyed by crossover if the operation is applied anywhere within its defining length, the probability that S will be destroyed is equal to Pc x 6 S)/ K — 1), where 6 S) is the defining length of S. Hence, the probability of survival ps = 1 — PcS S)/ K — 1), and equation 11.9 takes the updated form ... 

The pathophysiology of HL is defined by the presence of the RS cell in a grouping of lymph nodes. The RS cell is a large cell morphologically with a multinucleated structure with pronounced eosinophilic nucleoli.5 In the affected lymph nodes, the RS cells are contained in a reactive milieu of T lymphocytes, eosinophils, histiocytes, and plasma cells, which makes them difficult to distinguish from these background cells. The natural course of the disease, if left untreated, is less than a 5% probability of surviving 5 years. 

Areas of the North and South Atlantic, and North and South Pacific present continual extreme and hostile ambient conditions that make survival exposed to such conditions a very limited probability with adequate protection measures. In these locations the probability of survival is increased with the provision of a fixed safe refuge rather than the provision of an immediate means of escape. For offshore facilities historical evidence indicates that both helicopter and lifeboat mechanism may be unavailable in some catastrophic incidents. Remote onshore facilities may also experience severe winter conditions that also render this philosophy applicable. 

The obvious problem with this discussion is that it is circular - that encystment does occur and thus significantly decreases the size of motile cell populations. Low or nonexistent wintertime concentrations of tamarensis may thus reflect either a low probability of survival or the removal of many motile cells by cyst formation and deposition. 

From installation or birth, the valve or human has a probability of surviving that is the integral of the lifetime probability, which we can call p(t),... 

This measure is likely to be a reasonable proxy for disease-specific health outcomes for two reasons. First, the proportion of deaths occurring above a certain age can be interpreted as the probability of survival until that age, for example, age 65 (Lichtenberg 2005b). Second, there is a statistically positive relationship between life expectancy at birth and the proportion of deaths occurring above a specific age, based on comparisons of time series data within a country or cross-sectional data across countries. For example, with life expectancy at birth on the vertical axis and the proportion of deaths occurring above age 65 for the whole population at the horizontal axis using time series data from Taiwan for 1971-2002, there is a significantly positive relationship, for both males and females (Fig. 13.4). Life expectancy at birth increases as the age at death increases. 

Specifically, we found that a 10% increase in the stock of pharmaceutical innovation led to a 0.8-1.4% increase in the probability of survival to age 65. These results are consistent with findings in the recent literature that medical research in specific and technological change in medicine in general have a significant contribution to health outcomes (e.g.. Cutler and McClellan 2001a, b Murphy and Topel 2003b Cutler 2004). 

As shown in Table 13.3, the pharmaceutical innovation remains to have significantly positive impact on the probability of survival to age 65 after controlling for the effect of economic and social trends. However, the magnitude... 

Using data shown in Figure 13.4, we used ordinary least squares to estimate the effect of the probability of survival to age 65 on life expectancy at birth and found a significantly positive association between these two measures a 10% increase in probability of survival to age 65 was associated with a 1.3% increase in life expectancy. This result, combined with the estimates in Tables 13.2 and 13.3, implies that a 10% increase in the stock of pharmaceutical innovation would lead to an increase in life expectancy at birth by 0.10% (i.e., 0.8% X 1.3%) to 0.18% (1.4% x 1.3%). 

The research reported in this chapter has examined the association between pharmaceutical innovations and health outcomes, using the cumulative number of NME launches in Taiwan as a measure of innovations. Based on a disease-specific panel, we found a statistically significant, positive relationship between the stock of pharmaceutical innovation available in Taiwan s market and the probability of survival to age 65, after accounting for the economic and social trends. We investigated the effect of pharmaceutical innovation on life expectancy with two different approaches. Both approaches yielded similar results. Our low bound or conservative estimate suggests that a 10% increase in the stock of pharmaceutical innovation led to an increase in life expectancy at birth by about 0.1%. 

Amyotrophic lateral sclerosis (ALS) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons in the central nervous system. No cure has yet been found for ALS. The U.S. Food and Drug Administration (FDA) has approved riluzole as the first drug treatment for the disease. It delays the onset of ventilator-dependence or tracheostomy in selected patients. A Cochrane review states a 9% gain in the probability of surviving one year (see Miller et ah, 2007). 

Kaplan and Meier (1958) introduced a methodology for estimating, from censored survival data, the probability of being event-free as a function of time. If the event is death then we are estimating the probability of surviving and the resultant plots of the estimated probability of surviving as a function of time are called either Kaplan-Meier (KM) curves or survival curves. 

It is straightforward to obtain the estimated probability of surviving for various key time points from the Kaplan-Meier estimates. In the Packer et al. (2001) example, the estimated survival probability at 12 months in the carvedilol group was 0.886 compared to 0.815 in the placebo group, an absolute difference of 7.1 per cent in the survival rates. A standard error formula provided by Greenwood (1926) enables us to obtain confidence intervals for these individual survival rates and for their differences. 

Now to the calculation of the Kaplan-Meier survival probabilities. Using the above example, the estimated probability of surviving beyond month 1 is... 

The probability of surviving beyond month 2 is the probability of surviving beyond month 1 x the probability of surviving beyond month... 

Sterilization A process intended to kill or remove all types of microorganisms, including spores, and usually including viruses, with an acceptably low probability of survival... 

The fraction of M-tuplets which survive, or the probability of survival of an n-tuplet, is... 

Figure 3.17 Probability of survival of CH3CCI2F hydrate free samples plotted vs. the induction time. The triple liquid-water/hydrate/liquid-CF CC F equilibrium temperature is 281.6 K. The sample is cooled to 277.2 K (within 90 s), and held at this temperature until nucleation occurs and hydrate growth is detected. (Reproduced and modified from Ohmura, R., Ogawa, M., Yasuka, K., Mori, Y.J., J. Phys. Chem. B, 107, 5289 (2003). With permission from the American Chemical Society.)...

Evidence has also emerged on long-term survival in young women with a clear-cell adenocarcinoma of the vagina, 20% of whom had been exposed to diethylstilbestrol and 80% had not (33). The probabilities of survival at 5 and 10 years for diethylstilbestrol-associated cases were 84 and 78% respectively, compared with 69 and 60% for those not associated with diethylstilbestrol. These differences were not due to differences in clinical prognostic factors, but suggest differences in tumor behavior for as yet undetermined reasons. 

The goal of the biological validation procedure depends on the nature of the process. If the process is intended to sterilize only, the probability of survival approach is used. In this case, validation studies must determine a dry-heat cycle that will assure that the probability of survival of the microbial indicator is not greater than 10 If the process is intended to sterilize and depyrogenate, which occurs when the materials can withstand excessive heat, the overkill approach is used. The goal here is to validate a heating cycle that can produce a 12-log reduction in the biological indicator population. 

The medium should be exposed to steam under pressure in a validated sterilization cycle to achieve at least a 10"6 probability of survival of organisms within the medium. 

Nakajo A., Stiller C., Harkegard G. and Bolland O., 2006. Modeling of thermal stresses and probability of survival of tubular SOFC. Journal of Power Sources 158(1), 287-294. 

After each strong collision, the system, having been localized in the left or right well, resumes free tunneling from the diagonal state. Thus, after N collisions the probability of surviving in the left well is... 

---